ISOINDOLINDERIVATE

European patent · EP3204374 · In force

Register entry

Publication number
EP3204374
Application number
EP15778906
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Oct 6, 2015
Published
Aug 16, 2017
Granted
Apr 3, 2019
Protection ends at the latest
Oct 5, 2035
Next annual fee due
Oct 31, 2026
IPC classes
C07D 401/06 (2006.01)
C07D 487/04 (2006.01)
C07D 209/44 (2006.01)
A61K 31/4035 (2006.01)
A61P 25/16 (2006.01)
Priority
EP 14188150 08.10.2014
PCT application
PCT/EP2015/073057 06.10.2015
PCT publication
WO2016/055482 14.04.2016
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Nov 1, 2025

    Change

    Published in Swissreg on 01.11.2025

  2. Nov 1, 2024

    Change

    Published in Swissreg on 01.11.2024

  3. Nov 1, 2023

    Change

    Published in Swissreg on 01.11.2023

  4. Nov 1, 2022

    Change

    Published in Swissreg on 01.11.2022

  5. Dec 11, 2019

    Owner

    Owner
    UCB Biopharma SPRL, Allée de la Recherche 60, 1070 Brussels, Belgium → UCB Biopharma SRL, Allé de la Recherche 60, 1070 Brussels, Belgium

    Published in Swissreg on 11.12.2019

  6. Apr 3, 2019

    Granted

    Published in Swissreg on 03.04.2019

Parties

Holder

UCB Biopharma SRL

Allé de la Recherche 60, 1070 Brussels, BE

Inventor

ATES, Ali

B-1070 Brussels, BE

SANDS, Zara

B-1070 Brussels, BE

MATHIEU, Benoît

B-1070 Brussels, BE

SKOLC, David

B-1070 Brussels, BE

JNOFF, Eric

B-1070 Brussels, BE

VALADE, Anne

B-1070 Brussels, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.